Bessemer Group Inc. Buys New Stake in Meridian Bioscience, Inc. (VIVO)
Bessemer Group Inc. bought a new stake in shares of Meridian Bioscience, Inc. (NASDAQ:VIVO) in the 4th quarter, Holdings Channel reports. The firm bought 19,300 shares of the company’s stock, valued at approximately $270,000.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Advisor Group Inc. grew its position in Meridian Bioscience by 24.9% during the second quarter. Advisor Group Inc. now owns 7,720 shares of the company’s stock valued at $122,000 after buying an additional 1,537 shares during the period. Hartford Investment Management Co. bought a new stake in Meridian Bioscience during the third quarter valued at approximately $166,000. Eqis Capital Management Inc. bought a new stake in Meridian Bioscience during the third quarter valued at approximately $184,000. Nisa Investment Advisors LLC grew its position in Meridian Bioscience by 90.9% during the fourth quarter. Nisa Investment Advisors LLC now owns 13,020 shares of the company’s stock valued at $182,000 after buying an additional 6,200 shares during the period. Finally, UBS Asset Management Americas Inc. grew its position in Meridian Bioscience by 0.7% during the second quarter. UBS Asset Management Americas Inc. now owns 13,091 shares of the company’s stock valued at $206,000 after buying an additional 92 shares during the period. Institutional investors own 85.37% of the company’s stock.
Several analysts recently issued reports on VIVO shares. Zacks Investment Research lowered shares of Meridian Bioscience from a “hold” rating to a “sell” rating in a research report on Tuesday, October 24th. Canaccord Genuity boosted their target price on shares of Meridian Bioscience from $14.00 to $16.00 and gave the company a “hold” rating in a research report on Friday, January 26th. Finally, BidaskClub lowered shares of Meridian Bioscience from a “hold” rating to a “sell” rating in a research report on Saturday, February 3rd.
Meridian Bioscience (NASDAQ:VIVO) last posted its quarterly earnings results on Thursday, January 25th. The company reported $0.15 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.14 by $0.01. The business had revenue of $52.30 million during the quarter, compared to analyst estimates of $49.00 million. Meridian Bioscience had a net margin of 10.46% and a return on equity of 17.00%. The company’s revenue was up 11.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.15 earnings per share. sell-side analysts anticipate that Meridian Bioscience, Inc. will post 0.69 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Shareholders of record on Monday, February 5th will be given a $0.125 dividend. The ex-dividend date of this dividend is Friday, February 2nd. This represents a $0.50 dividend on an annualized basis and a dividend yield of 3.55%. Meridian Bioscience’s payout ratio is currently 98.04%.
About Meridian Bioscience
Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.
Want to see what other hedge funds are holding VIVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Meridian Bioscience, Inc. (NASDAQ:VIVO).
Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.